Education
About Us
Working with TipRanks
Follow Us
Exagen Inc (XGN)
NASDAQ:XGN
XGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.38 - $10.34
Previous CloseN/A
Volume15.94K
Average Volume (3M)210.81K
Market Cap
$214.32M
Enterprise Value$142.35M
Total Cash (Recent Filing)$30.03M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 18, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding22,003,641
10 Day Avg. Volume164,430
30 Day Avg. Volume210,813
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue2.42
Enterprise Value/Gross Profit4.07
Enterprise Value/Ebitda-11.66
Forecast
1Y Price Target
$11.67Price Target Upside19.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement anticipates reaching AEBITDA positivity in the fourth quarter if revenue hits the high end of its revised guidance.
Product InnovationXGN is feeling good about its new biomarker launches and is optimistic that its new biomarkers can pull forward even higher ASPs.
Stock Price IncreaseShares of XGN are up a very strong 105% as the company seems to be finally gaining some 'valuation support' for the good operational work it is putting in.
Bears Say
Cash Burn ConcernsThe focus on cutting the cash burn via narrowing the commercial efforts to focus on profitable accounts is paying off.
Market Penetration ChallengesWith <10% market penetration and an expanding sales force, management sounds confident that this volume growth is sustainable.
Exagen News
XGN FAQ
What was Exagen Inc’s price range in the past 12 months?
Exagen Inc lowest stock price was $2.38 and its highest was $10.34 in the past 12 months.
What is Exagen Inc’s market cap?
Exagen Inc’s market cap is $214.32M.
When is Exagen Inc’s upcoming earnings report date?
Exagen Inc’s upcoming earnings report date is Nov 18, 2025 which is in 62 days.
How were Exagen Inc’s earnings last quarter?
Exagen Inc released its earnings results on Jul 29, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.06.
Is Exagen Inc overvalued?
According to Wall Street analysts Exagen Inc’s price is currently Undervalued.
Does Exagen Inc pay dividends?
Exagen Inc does not currently pay dividends.
What is Exagen Inc’s EPS estimate?
Exagen Inc’s EPS estimate is -0.16.
How many shares outstanding does Exagen Inc have?
Exagen Inc has 22,003,641 shares outstanding.
What happened to Exagen Inc’s price movement after its last earnings report?
Exagen Inc reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went up 14.344%.
Which hedge fund is a major shareholder of Exagen Inc?
Currently, no hedge funds are holding shares in XGN
Exagen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (19.82% Upside)
$11.67 (19.82% Upside)
Blogger Sentiment
Bullish
XGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 478.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $200.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
223.58%
12-Months-Change
Fundamentals
Return on Equity
-87.94%
Trailing 12-Months
Asset Growth
19.17%
Trailing 12-Months
Company Description
Exagen Inc
Exagen Inc. is a biotechnology company focused on developing and commercializing innovative diagnostic solutions for autoimmune diseases. The company operates primarily in the healthcare sector, with a strong emphasis on providing advanced laboratory testing services that help physicians diagnose and manage conditions such as lupus and other related autoimmune disorders. Exagen's core products include its proprietary AVISE® testing platform, which offers a range of tests designed to improve patient care through more accurate and timely diagnoses.
XGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Exagen, marked by record revenue growth, successful biomarker launches, and strategic leadership additions. While there are challenges related to operating losses and increased expenses, the company's strong cash position and positive revenue guidance indicate resilience and growth potential.View all XGN earnings summariesXGN Stock 12 Month Forecast
Average Price Target
$11.67
▲(19.82% Upside)
Technical Analysis
Ownership Overview
12.79% Insiders
3.60% Mutual Funds
22.81% Other Institutional Investors
57.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---